¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦

ÀÎõÀý¹ÚÀ¯»ê ÇÑÀÇ¿ø ÁÖ¸»Áø·á

ÃßõÇϱâ
ÇÑÀÇ¿ø À̹øÁÖ BEST
 
#ÀÎõÀý¹ÚÀ¯»ê, #ÀÎõÀý¹ÚÀ¯»êÇÑÀÇ¿ø, #»ý¸®µµº®, #ÀÎõ»ý¸®µµº®, #Àý¹ÚÀ¯»êÇÑÀÇ¿ø, #»ý¸®µµº®ÇÑÀÇ¿ø, #ÀÎõ»ý¸®µµº®, #ÀÎõÀý¹ÚÀ¯»ê ÀÎõÀý¹ÚÀ¯»ê,,ÀÎõÀý¹ÚÀ¯»êÇÑÀÇ¿ø,,»ý¸®µµº®,,ÀÎõ»ý¸®µµº®,,Àý¹ÚÀ¯»êÇÑÀÇ¿ø,,»ý¸®µµº®ÇÑÀÇ¿ø,,ÀÎõ»ý¸®µµº®,,ÀÎõÀý¹ÚÀ¯»ê ¾È³çÇϼ¼¿ä. ÀÎõÀý¹ÚÀ¯»ê ÀÎõ ÇÑÀÇ¿ø ãÀ¸½Ã´Â ºÐµéÀÌ ¸¹À¸½Åµ¥¿ä ÀÎõÀý¹ÚÀ¯»ê ÀÎõ Ä¡·á ãÀ¸½Ã´Â ºÐµéÀÌ ¹Ì¿ÃÇÑÀÇ¿ø ÀÎõÁ¡À» ÀÚÁÖ Ã£À¸½Ã´Âµ¥¿ä. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â»ý¸®µµº®, Ãâ»êÇѾà, ºÒÀÓ¼ö¼ú, »ý¸®ÁõÈıº, ¼¼±Õ¼ºÁú¿°, ºÒ±ÔÄ¢ÇÑ»ý¸®, Æ®¸®Äڸ𳪽ºÁú¿°, È­ÇÐÀûÀ¯»ê¸öÁ¶¸®, È­ÇÐÀûÀ¯»êÈÄÀÓ½Å, ¹«¿ù°æÄ¡·á, Áú°ÇÁ¶Áõ, Æó°æ±âÁõ»ó, »ý¸®ÅëÇѾà, À¯»êÇѾà, ´Þ»ý»ê, ¼ÒÆļö¼ú, 20´ëÀڱñÙÁ¾, »ý¸®ÀüÁõÈıºµÎÅë, °è·ùÀ¯»êÈĸöÁ¶¸®, È­ÇÐÀûÀ¯»êÇÏÇ÷, ³­¼Ò³¶Á¾Ä¡·á, ºÒÀÓÄ¡·á, ¿©¼º¼¼Á¤Á¦, »êÈÄ°ü¸®ÇÑÀÇ¿ø, ÀÚ±ÃÃâÇ÷µî ´Ù¾çÇÑ ¹®ÀǸ¦ ÁÖ°í °è½Ê´Ï´Ù. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â ´Ù¾çÇÑ È¯ÀںеéÀÌ ³»¿øÇÏ°í °è½Ã¸ç °³Àκ° Áõ»ó°ú üÁú¿¡ µû¶ó Áõ·ùÇѾà, Àû¿Ü¼±Ä¡·á, °æÃß°ßÀÎÄ¡·á, µµÀοä¹ý, ¿ªÇÐÄ¡·á, ÆĶóÇÉ¿å, ÀÌ°­·¹ÀÌÀú, ¸ÆÆÄ°Ë»ç, silver spike point, °æÇÇ°æ±ÙÇѳÿä¹ý, À¯ºñ¿À¸ÆÆÄ, Çâ±â¿ä¹ý, NMES, ÀåħÀü±âÀڱؼú, °æ¶ôÇâ±â¿ä¹ý, ±â´ÉÀûÀü±âÀÚ±ØÄ¡·á, ÇѹæÁ¤½Å¿ä¹ý, ¹°¸®Ä¡·á, ¿Â¼º¾îÇ÷¾àħ, Çâ±âÀÚ°¡¿ä¹ý, ¸ÂÃãÇÑ¾à µî ÇÕ¸®ÀûÀÌ°í È¿°úÀûÀÎ ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù ¹Ì¿ÃÇÑÀÇ¿øÀº Àü±¹ 20¿©°³ ÁöÁ¡¿¡¼­ Áø·áÁßÀ̸ç Àü³² °íÈﱺ µÎ¿ø¸é, ºÎ»ê µ¿·¡±¸ ¾È¶ô1µ¿, °æ³² ÁøÁֽà Á߾ȵ¿, °æ±â Çϳ²½Ã ÇÏ»ç⵿, ÀÎõ ¼­±¸ ¼®³²3µ¿, ÃæºÏ Á¦Ãµ½Ã ÀǸ²µ¿, °æ±â ¾È¼º½Ã ½Å¸ð»êµ¿, °æºÏ Ä¥°î±º µ¿¸í¸é, °æ³² â¿ø½Ã ¸¶»êÇÕÆ÷±¸ ¼ö¼ºµ¿, Àü³² ¿©¼ö½Ã ºÀ°èµ¿, ÀÎõ ³²±¸ ¿ëÇöµ¿, °æ³² â¿ø½Ã ¼º»ê±¸ »ïÁ¤ÀÚµ¿, ºÎ»ê ±ÝÁ¤±¸ ¼­1µ¿, ÀüºÏ ±èÁ¦½Ã ¹é±¸¸é, Àü³² Áøµµ±º °í±º¸é, ÀüºÏ ±èÁ¦½Ã ºÀ³²¸é, Àü³² ³ªÁֽà ¹®Æò¸é, °­¿ø ÀÎÁ¦±º ±â¸°¸é, °æ±â Àǿսà °íõµ¿, Ãæ³² ±Ý»ê±º Áø»ê¸é, ºÎ»ê »çÇϱ¸ ±«Á¤1µ¿, Àü³² ¹«¾È±º ¸Á¿î¸é, °æ³² â³ç±º °í¾Ï¸é, °æ³² ÇÕõ±º ´ëº´¸é, °æ±â ¾È¼º½Ã µµ±âµ¿, ¿ï»ê ³²±¸ °³¿îµ¿, Àü³² ´ã¾ç±º ´ã¾çÀ¾, Àü³² ³ªÁֽà °ø»ê¸é, ÀÎõ Áß±¸ ¼±¸°µ¿, °æ³² ÇÕõ±º ´ëº´¸é, µî ´Ù¾çÇÑ Áö¿ª Áֹε鲲¼­ ³»¿øÇÏ°í °è½Ê´Ï´Ù ÀÎõÀý¹ÚÀ¯»êÄ¡·á ãÀ¸½Ã´Â µ¿±¸, ¿µÁ¾µµ, µµ¸²µ¿, ¼­Ã¢µ¿, ¼±Çе¿, Á¤¿Õµ¿, ¹®Çе¿, ¼Û¿ùµ¿, ¼Û¸²µ¿, ¼þÀǵ¿, ÀÎõ³íÇö, ¿Á·Ãµ¿, ¼Û»ê¸é, ºñºÀ¸é, ¿¬¼öµ¿, ±¸¿ùµ¿, °è¾ç±¸, °Ë´Ü, °¡Áµ¿, Á־ȿª, ¼Ûµµ½Åµµ½Ã, ³²¾çÀ¾, ÀÎõ¼­±¸, Áß±¸, ¼Ûµµ±¹Á¦µµ½Ã, ¸¸¼öµ¿, »óµ¿, ¿î³²µ¿, ºÎõ, ¼®³²µ¿, ¸Å¼Û¸é, ´ëºÎµµ, ¸¶µµ¸é, °ü±³µ¿, ÆÈź¸é µî ÀÎõ Áö¿ª Áֹε鲲¼­ ¹Ì¿ÃÇÑÀÇ¿øÀÎõÁ¡À» ¹æ¹®ÇÏ°í °è½Ê´Ï´Ù. ´õ »ìÆ캸±â 1. Steed H, Chapman W, Laframboise S. Endometriosis-associated ovarian cancer: a clinicopathologic review. J Obstet Gynaecol Can 2004; 26:709. 2. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016; 4:CD012165. 3. Murphy AA, Green WR, Bobbie D, et al. Unsuspected endometriosis documented by scanning electron microscopy in visually normal peritoneum. Fertil Steril 1986; 46:522. 4. Klenov VE, Potretzke TA, Sehn JK, Thaker PH. Postmenopausal Invasive Endometriosis Requiring Supralevator Pelvic Exenteration. Obstet Gynecol 2015; 126:1215. 5. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90:6364. 6. Blanco RG, Parithivel VS, Shah AK, et al. Abdominal wall endometriomas. Am J Surg 2003; 185:596. 7. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:3835. 8. Husby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 2003; 82:649. 9. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139. 10. Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril 2004; 81:493.
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ÀÎõÀý¹ÚÀ¯»ê ÇÑÀÇ¿ø ÁÖ¸»Áø·á""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÎõºÎºñµ¿¿° ÇÑÀÇ¿ø ¾ðÁ¦³ª Æí¾ÈÇÑ°÷
´ÙÀ½±Û ÀÎõ½ÀÁø Ä¡·á °ÆÁ¤³¡
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
372 º½º½ÇÑÀÇ¿ø 3¿ù À̺¥Æ® 0 658 2018-03-03
371 ÀÌõ´ÙÀ̾îÆ® ¹Ì¿ÃÇÑÀÇ¿ø üÁúº° ÇѾà Ãßõ 2 2,454 2018-03-02
370 õȣÇÏ´Ãü - ÇǺÎÁúȯ Ä¡·áÇϼ¼¿ä 0 1,310 2018-02-28
369 °æÈñº½ºûÇÑÀÇ¿ø - µ¿ÀÛ±¸ ´ÙÀ̾îÆ® ÇÒÀÎ À̺¥Æ® ÁøÇà Áß 0 1,507 2018-02-28
368 ±â¿îÂùÇÑÀÇ¿ø Á߶û±¸¿¡¼­ ¼Õ²ÅÈ÷´Â ÀÌÀ¯. [1] 0 1,501 2018-02-27
367 ¼ö¿ø±³Åë»ç°íÄ¡·á ¹ã¿¡µµ ¿­¸°°÷ 0 1,055 2018-02-23
366 ƽÀå¾Ö º´¿ø ÇÑÀÇ¿øÀ¸·Î °¡´ÂÀÌÀ¯? 0 1,224 2018-02-22
365 ¼ö¿ø È­º´ Ä¡·á ¸íÀýÁö³ª°í ƯÈ÷¸¹ÀºÀÌÀ¯ 0 604 2018-02-22
364 ¼öÁö±¸Ã»¿ª ºñ¿° ÇÑÀÇ¿ø 2¿ù À̺¥Æ® ÇÒÀÎ °øÁö 0 2,767 2018-02-02
363 Á¤ÀÚµ¿ ÇÑÀÇ¿ø) 2¿ù ´ÙÀ̾îÆ® À̺¥Æ® - À±¾Ø±èÇÑÀÇ¿ø 0 1,307 2018-02-02
362 º½º½ÇÑÀÇ¿ø 2¿ù À̺¥Æ® 0 637 2018-02-02
361 »êº»ÇÑÀÇ¿ø ÇÊÇÑÀÇ¿ø ¿¡¼­ ü°èÀûÀÎ Áø·á¸¦ 0 873 2018-01-17
360 ±¤±³ÇÑÀÇ¿ø - 1¿ù À̺¥Æ® °øÁø´Ü °æ¿Á°í »õÇØ¿¡´Â °Ç°­ ¼±¹°Çϼ¼¿ä~ °æ.. 0 1,742 2018-01-02
359 2018³â º½º½ÇÑÀÇ¿ø 1¿ù ½Å³â¸ÂÀÌ ºò À̺¥Æ® 0 516 2018-01-02
358 ¾È»ê¶óÀÓÇÑÀÇ¿ø 1¿ù À̺¥Æ® 2 1,519 2018-01-02
357 ¼÷ÁöȲ°ú ¹«¸¦ °°ÀÌ ¸ÔÀ¸¸é ¸Ó¸®Ä«¶ôÀÌ Èò»öÀ¸·Î º¯ÇÑ´Ù´Â ¸»ÀÌ ¸Â½À´Ï.. 6 909 2017-12-10
356 <¿¹½ºº»ÇÑÀÇ¿ø> ¹Î¶ô2Áö±¸ 12¿ù À̺¥Æ® "¾Æ±âÁÖ»ç+¿ÀÅäMTS" 0 2,759 2017-12-06
355 ¸ñÇ¥´Þ¼º À̺¥Æ® -12¿ù ¹Ú°æÈÆÇÑÀÇ¿ø ºÎ»ê´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÔ´Ï´Ù 0 1,384 2017-12-06
354 º½º½ ÇÑÀÇ¿ø 12¿ù À̺¥Æ® 0 648 2017-12-06
353 ¿©·¯ºÐ ÇѹæÄ¡·á ¹ÞÀ¸¼¼¿ä [1] 5 1,703 2017-12-02
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷